Lopinavir/ritonavir + tenofovir Dual Therapy versus Lopinavir/ritonavir-Based Triple Therapy in HIV-Infected Antiretroviral Naïve Subjects: The Kalead Study

Journal of Antivirals and Antiretrovirals

Volumn 2, Issue 4, 2010, Pages 056-062

  Pinola, Mari ^a   Lazzarin, Adriano ^b   Antinori, Andrea ^c   Carosi, Giampiero ^d   Di Perri, Giovanni ^e   Moroni, Mauro ^f   Vullo, Vincenzo ^g   Pastore, Giuseppe ^h   Norton, Michael ⁱ   di Luzio Paparatti, Umberto ^a  

^a ABBOTT DIAGNOSTICS   (Italy)

^b SAN RAFFAELE HOSPITAL   (Italy)

^c NATIONAL INSTITUTE FOR INFECTIOUS DISEASES L SPALLANZANI   (Italy)

^d UNIVERSITY OF BRESCIA   (Italy)

^e UNIVERSITY OF TURIN   (Italy)

^f UNIVERSITY OF MILAN   (Italy)

^g SAPIENZA UNIVERSITY OF ROME   (Italy)

^h POLICLINICO   (Italy)

ⁱ ABBOTT LABORATORIES   (United States)

Author keywords

ARV therapy; Dual therapy; Lopinavir; NRTI; Protease inhibitors; Tenofovir

Indexed keywords

ABACAVIR PLUS LAMIVUDINE; CHOLESTEROL; CREATININE; GLUCOSE; LAMIVUDINE PLUS ZIDOVUDINE; LOPINAVIR PLUS RITONAVIR; PHOSPHATE; TENOFOVIR; TRIACYLGLYCEROL; VIRUS RNA;

ADULT; ARTICLE; ASTHENIA; CD4 LYMPHOCYTE COUNT; CLINICAL PROTOCOL; COMBINATION CHEMOTHERAPY; COUGHING; CREATININE BLOOD LEVEL; CREATININE CLEARANCE; DIARRHEA; DIZZINESS; DRUG EFFICACY; DRUG ERUPTION; DRUG FEVER; DRUG INDUCED HEADACHE; DRUG TOLERABILITY; DRUG WITHDRAWAL; DYSLIPIDEMIA; DYSPNEA; GASTROINTESTINAL PAIN; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS 1; HUMAN IMMUNODEFICIENCY VIRUS 1 INFECTION; HYPERTRIGLYCERIDEMIA; LYMPHADENOPATHY; LYMPHOPROLIFERATIVE DISEASE; MAJOR CLINICAL STUDY; MALE; NAUSEA; NECK PAIN; NEPHROTOXICITY; PHOSPHATE BLOOD LEVEL; PROSPECTIVE STUDY; QUALITY OF LIFE; RANDOMIZED CONTROLLED TRIAL; SIDE EFFECT; THORAX PAIN; TREATMENT OUTCOME; VIREMIA; VIRUS MUTATION; VOMITING;

EID: 79251531112     PISSN: None     EISSN: 19485964     Source Type: Journal    
DOI: 10.4172/jaa.1000024     Document Type: Article

References (14)

1. Cameron DW, Heath-Chiozzi M, Danner S, Cohen C, Kravick S, et al. (1998) Randomised placebo-controlled trial of ritonavir in advanced HIV-1 disease. Lancet 351: 543-549.
2. D'Arminio Monforte A, Cozzi-Lepri A, Rezza G, Pezzotti P, Antinori A, et al. (2000) Insights into the reasons for discontinuation of the first highly active antiretroviral therapy (HAART) regimen in a cohort of antiretroviral naive patients. AIDS 14: 499-507.
3. Gazzard B, Bernard AJ, Boffito M, Churchill D, Edwards S, et al. (2006) British HIV Association guidelines for the treatment of HIV-infected adults with antiretroviral therapy. HIV Med 7: 487-503.
4. Hammer SM, Eron JJ Jr, Reiss P, Schooley RT, Thompson MA, et al. (2008) Antiretroviral Treatment of Adult HIV Infection: 2008 Recommendations of the International AIDS Society-USA Panel. 300: 555-570.
5. Hammer SM, Squires KE, Hughes MD, Demeter LM, Currier JS, et al. (1997) A controlled trial of two nucleoside analogues plus indinavir in persons with human immunodeficiency virus infection and CD4 cell counts of 200 per cubic millimeter or less. N Engl J Med 337: 725-733.
6. Hicks C, King MS, Gulick RM, White AC Jr, Eron JJ Jr, et al. (2004) Long-term safety and durable antiretroviral activity of lopinavir/ritonavir in treatment-naïve patients: 4 year follow-up study. AIDS 18: 775-779.
7. Molina JM, Podsadecki TJ, Johnson MA, Wilkin A, Domingo P, et al. (2007) A lopinavir/ritonavir-based once-daily regimen results in better compliance and is non-inferior to a twice-daily regimen through 96 Weeks. AIDS Res Hum Retrovir 23: 1505-1514.
8. Murphy RL, da Silva BA, Hicks CB, Eron JJ, Gulick RM, et al. (2008) Sevenyear efficacy of a lopinavir/ritonavir-based regimen in antiretroviral-naïve HIV-1-infected patients. HIV Clin Trials 9: 1-10.
9. Murri R, Ammassari A, Gallicano K, De Luca A, Cingolani A, et al.(2000) Patient-reported nonadherence to HAART is related to protease inhibitor levels. J Acquir Immune Defic Syndr 24: 123-128.
10. Palella FJ Jr, Delaney KM, Moorman AC, Loveless MO, Fuhrer J, et al. (1998) Declining morbidity and mortality among subjects with advanced human immunodeficiency virus infection. N Engl J Med 338: 853-860.
11. Panel on Antiretroviral Guidelines for Adult and Adolescents. Guidelines for the use of antiretroviral agents in HIV-1-infected adults and adolescents. Department of Health and Human Services. December 1, 2009; 1-161.
12. Riddler SA, Haubrich R, Di Rienzo AG, Peeples L, Powderly WG, et al. (2008) Class-sparing regimens for initial treatment of HIV-1 infection. N Engl J Med 358: 2095-2106.
13. Trotta MP, Ammassari A, Cozzi-Lepri A, Zaccarelli M, Castelli F, et al. (2003) Adherence to highly active antiretroviral therapy is better in patients receiving non-nucleoside reverse transcriptase inhibitor-containing regimens than in those receiving protease inhibitor-containing regimens. AIDS 17: 1099-1102.
14. Walmsley S, Bernstein B, King M, Arribas J, Beall G, et al. (2002) Lopinavirritonavir versus nelfinavir for the initial treatment of HIV infection. N Engl J Med 346: 2039-2046.